基石药业（苏州）有限公司 CSTONE PHARMACEUTICALS
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
CStone Pharmaceuticals announces initiation of CS1001 Phase I Study in U.S., patient enrollment under way 2018-12-21 17:50
CStone Pharmaceuticals Appoints Former MSD Global Oncology Early Development Executive Director Archie Tse, M.D., Ph.D., as the newly established SVP, Chief Translation Medicine Officer 2018-12-10 15:38
CStone initiates a bridging Phase I clinical trial for PD-1 antibody CS1003 with first patient dosed in China 2018-11-19 12:54
CStone announces first patient dosed in Phase I study in China for MEK inhibitor CS3006 2018-10-30 10:28
CStone Receives US FDA IND Approval for Recombinant PD-1 mAb CS1003 2018-10-24 10:08
CStone Receives U.S. IND Approval for PD-L1 Antibody CS1001 2018-10-16 16:48
CStone's Anti-CTLA-4 Antibody CS1002 Receives IND Approval in China 2018-08-28 10:16
CStone's MEK Inhibitor CS3006 Receives IND Approval in China 2018-07-30 12:51
CStone's PD-1 inhibitor CS1003 receives clinical trial approval in China 2018-07-12 12:45
CStone enrolls first patient in Phase I study for MEK inhibitor CS3006 in Australia 2018-06-20 19:07
CStone Pharmaceuticals Initiates Two Pivotal Phase II Studies of the Anti-PD-L1 Monoclonal Antibody CS1001 2018-06-13 15:09
CStone announces first patient dosing with anti-PD-1 antibody CS1003 in Phase I study in Australia 2018-05-14 18:36
CStone Raises $260 million in Series B Financing to Advance Novel Cancer Therapies 2018-05-09 11:18
CStone announces first patient dosed with anti-CTLA-4 antibody CS1002 of a Phase I study in Australia 2018-05-04 14:47
CStone's anti-CTLA-4 antibody CS1002 filed for clinical trial approval in Australia 2017-12-29 21:00
CStone files CS1003, an anti-PD-1 antibody, for clinical trial approval in Australia 2017-12-28 10:45
CStone files MEK inhibitor CS3006 for clinical trial approval in Australia 2017-12-27 15:41
Opening Ceremony of CStone Pharmaceuticals' Suzhou Translational Medicine Research Center and an associated Immuno-Oncology Forum was Successfully Held in Suzhou 2017-11-03 14:16
CStone Pharmaceuticals Announces Dosing the First Patient of CS1001: China's First Fully Human, Full-length Anti-PD-L1 Monoclonal Antibody 2017-10-20 20:50
China's First Fully Human, Full-length Anti-PD-L1 Monoclonal Antibody Receives Approval to Initiate Clinical Trials by the China Food and Drug Administration 2017-07-17 20:50
1 3 4 5 6 7